

## MINI-REVIEW

# Implementation of Proteomics for Cancer Research: Past, Present, and Future

Parisa Karimi<sup>1\*</sup>, Armin Shahrokni<sup>2</sup>, Mohammad R Nezami Ranjbar<sup>3</sup>

### Abstract

Cancer is the leading cause of the death, accounts for about 13% of all annual deaths worldwide. Many different fields of science are collaborating together studying cancer to improve our knowledge of this lethal disease, and find better solutions for diagnosis and treatment. Proteomics is one of the most recent and rapidly growing areas in molecular biology that helps understanding cancer from an omics data analysis point of view. The human proteome project was officially initiated in 2008. Proteomics enables the scientists to interrogate a variety of biospecimens for their protein contents and measure the concentrations of these proteins. Current necessary equipment and technologies for cancer proteomics are mass spectrometry, protein microarrays, nanotechnology and bioinformatics. In this paper, we provide a brief review on proteomics and its application in cancer research. After a brief introduction including its definition, we summarize the history of major previous work conducted by researchers, followed by an overview on the role of proteomics in cancer studies. We also provide a list of different utilities in cancer proteomics and investigate their advantages and shortcomings from theoretical and practical angles. Finally, we explore some of the main challenges and conclude the paper with future directions in this field.

**Keywords:** Proteomics - cancer - biomarkers - mass spectrometry - bioinformatics

*Asian Pac J Cancer Prev*, **15** (6), 2433-2438

### Introduction

Cancer is the leading cause of the death worldwide, which account for approximately 13% of all deaths each year (Ferlay et al., 2010). Only in 2013, a total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States (Siegel et al., 2013). Since 1990, the death for all cancers together has decreased by only 1% per year, a decline due to a combination of factors, including prevention specifically reductions in tobacco consumption, improvements in treatment of some cancers, and early detections of a few specific cancers (Edwards et al., 2010).

New treatments for several cancers decreased the death rates significantly; however, advances in cancer treatment and improvements outcomes have been modest during past decades, and current treatments represent limited efficacy against advanced cancers (Shahrokni and Karimi, 2012). Although drugs and surgery can be effective for cancers in early stages, they usually briefly extend survival of patients with metastatic cancers (Martin et al., 2010). In fact, advances in cancer treatment and improvements outcomes have been modest during past decades (Etzioni et al., 2003). A great deal of researches is invested to improve treatments for advanced cancers, since most

people who develop cancer have advanced disease at the time of diagnosis. For instance, among patients with breast, colorectal, and lung cancers in the United States, 34%, 57%, and 72% have metastatic cancer at the time of diagnosis (Etzioni et al., 2003). Thus, early detection can significantly reduce cancer mortality (Etzioni et al., 2003).

The advantages of early detection of cancer are to identify cancer while still localized and curable, prevent the mortality, and reduce the morbidity and cost (Smith et al., 2002; Kamangar and Karimi, 2013; Karimi et al., 2013). In another word, early detection generally means more opportunities for intervention that ultimately lead to improvement in patient outcomes (Karimi et al., 2013). Although early detection of cancer is the goal of majority of researches in cancer field since decade ago, relatively few early detection approaches have been proven sufficiently effective and practical (Etzioni et al., 2003). Biomarkers are one of the key concepts of early detection of cancer (Pepe et al., 2001), and defined by National Cancer Institute (NCI) as "...the biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease". The ideal biomarker should be easily detectable, highly sensitive and specific for its

<sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, <sup>2</sup>Memorial Sloan Kettering Cancer Center, Geriatric Oncology Service, New York, <sup>3</sup>Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, VA, USA. \*For correspondence: [pkarimi@jhsph.edu](mailto:pkarimi@jhsph.edu)

target phenotype, and economically feasible (IBM Corp. Released 2011. IBM SPSS Statistics for Windows). A biomarker may be used to monitor the body responses to a treatment for cancer (Pepe et al., 2001). Although the survival rate of cancer patients has dramatically increased in the last two decades, newer diagnostic methods with improved sensitivity and specificity are essential for the proper detection and prognosis of cancer that highlight the role of “omics” (Wulfschlegel et al., 2003; Bhati et al., 2012). The conventional approach to cancer research was the discovery of biomarkers through the analysis of serum or tissue, for decades (Pepe et al., 2001). The major obstacles for this kind of research were the broad range of serum proteome as biomarkers and the availability of tissue samples (Pepe et al., 2001).

## Definition of Proteomics

Proteomics is the science of the large-scale and comprehensive study of a specific proteome in order to understand the details of changes in cells (Wulfschlegel et al., 2003). The aim of proteomics is to gain information on protein abundances, their variations and modifications, and their interacting partners and networks (Wulfschlegel et al., 2003).

## History of Cancer Proteomics

On February 2002, the detailed map of the Human Genome Project was completed, which is known as the beginning of the post-genome era (Kent et al., 2002; Rezaee et al., 2013). Thereafter, scientists were attracted to the research on cancer genome and proteome (Ardekani et al., 2008). The cancer genome project was initiated in August 2006, while the human proteome project was officially initiated in April 2008 (Hudson et al., 2010). Since then, international associations and government agencies have been injecting huge research funds into cancer proteomic studies, making it one of the fastest growing research fields (Li et al., 2011).

## Role of Proteomics in Cancer Research

The detection and treatment of cancer depends on the deep understanding of molecular basis for cancer initiation, progression, and efficacious treatment, which is based on the discovery of unique biomarkers (Hanash et al., 2011). Although recent progress in cancer genomics has been rapid during the past few years, it only provides a glimpse of what may occur as dictated by the genetic code (Brower, 2011). In reality, scientists still need to measure what is happening in a patient in real time, which means finding tell-tale proteins as a clue to the biological processes of cancer development (Cao et al., 2011). This is because genes are only the “recipes” of the cell, while the proteins encoded by the genes are ultimately the functional players that drive both normal and cancer physiology (Ghabaee et al., 2009; Chang et al., 2011). The accessibility of cancer-related proteins in tissues and body fluids has triggered extensive protein-focused research to detect biomarkers (Martin et al.,

2010). Proteomics enables the scientists to interrogate a variety of biospecimens for their protein contents and measure the concentrations of these proteins (Poste, 2012). In other words, proteomics provide scientists and clinicians with a powerful tool to understand the different processes involved in cancer development and progression in hope to identify biomarkers specific for these cellular processes along with those indicating efficacious therapeutic intervention (Hainaut and Plymoth, 2011). Also, another way of understanding real time activities in living samples is to measure metabolome. Metabolites are small biomolecules interacting with proteins helping various functions to in cells and body fluids.

## Utilized Tools in Cancer Proteomics

*Necessary equipment and technologies for cancer proteomics are as follow*

**Mass Spectrometry:** Mass spectrometry (MS) is a novel and evolving technology that detect and quantify proteins in a complex biological matrix (Walther and Mann, 2010). It is usually coupled with liquid chromatography (LC) or gas chromatography (GC) to reach a better separation by including another dimension specifically for untargeted analysis (Maurer, 2010). Mass spectrometry methods are very precise, and could distinguish proteins that differ in composition by a single hydrogen atom that is the smallest atom (Gstaiger and Aebersold, 2009). Despite its potential, MS technologies are not yet capable to separate the complex protein mixtures from unprocessed human biospecimens (Wang et al., 2009). Other technologies such as organelle, protein fractionation, and affinity capture have been developed to reduce the complexity of proteins in biospecimens by enriching for a subset of proteins of interest (Boja and Rodriguez, 2012). In addition, these technologies improve the sensitivity of the instruments for detection and quantification of proteins (Baker et al., 2012).

**Protein Microarrays:** Protein microarrays are powerful tools to capture and measure proteins from biospecimen (Stoevesandt et al., 2009). A protein microarray typically consists of a small piece of plastic or glass coated with thousands of capture reagents (molecules that can grab specific proteins) (Chandra et al., 2011). By using this technology, scientists could isolate and study many potential biomarker proteins (Chandra et al., 2011). Protein microarrays can be miniaturized to contain tens of thousands of capture features arranged in a grid, each specific for a certain type of a protein (Mishra and Verma, 2010). Thus, they are considered a multiplexed device, and can test for multiple biomarkers simultaneously, which is essential for clinical use (Rusling et al., 2010).

**Nanotechnology:** Nanotechnology is the creation of manufacturing devices and components, ranged from 1 to 100 nanometers (Nicolini and Pechkova, 2010). Nanotechnology devices have the potential to significantly expand the capabilities of proteomics, e.g. addressing current limitations in selectively reaching a target protein in vivo through physical and biological barriers, detecting low abundance targets, and providing a “toolbox” to translate the discovery of protein biomarkers to novel

therapeutic and diagnostic tests (Collins et al., 2009). Typical nano-devices are including nanoparticles used for the targeted delivery of anticancer drugs, energy-based therapeutics, and imaging contrast reagents (Sadat Tabatabaei Mirakabad et al., 2014). Moreover, nanowires arrays can be used in biosensors that measure minute quantities of biomarkers in biological fluids (Ray et al., 2011).

**Bioinformatics:** The role of bioinformatics in cancer proteomics include data modeling and database design, data interoperability and comparison, gene and protein expression analysis, structural predictions, vocabularies and ontologies, and modeling for systems biology (Li et al., 2002). Thus, the development of new bioinformatics tools for integrative analysis of genomic and proteomic data is necessary to drive the collaborative, multidisciplinary effort required to drive discovery from the laboratory to clinical practice (Strassberger et al., 2010). Bioinformatics can improve the quality and accuracy of the study if it is involved from the initiation phase by developing, examining, and refining statistically sound hypotheses (Ressom et al., 2012). Moreover, it helps to investigate appropriate experimental designs and conclude the minimum needed sample size and population specifications in each study (Varghese et al., 2012). Also, it is the key to implementation of practical algorithms and realization of accurate hypothesis testing methods (Ressom et al., 2012). Thus, it is very critical to infer true differences, e.g. real protein biomarkers, across samples by using proper statistical learning and artificial intelligence approaches, which have been modified and adapted for the specific problem at hand (Ressom et al., 2012). In addition, this utility enables researchers from different areas to understand, communicate, and interpret data by employing advanced information retrieval systems and data visualization techniques (Nezami Ranjbar et al., 2013). Finally, bioinformatics is required for integration of data from different studies and technologies to achieve better understanding of the underlying biological

phenomena (Gortzak-Uzan et al., 2007). This can be done by utilization and development of network-based data analysis. For example, there are several tools to study the known pathways for different types of interactions, while protein-protein interactions (PPI) are not the only case of biomolecule interactions. There are still many other different types of interactions such as gene-protein or protein-metabolite interactions. However, at the present time, there are quite few tools that provide integration of multiple types of interaction networks (Rual et al., 2005).

**Biospecimens:** Current cancer research has come to rely heavily on the quality of biospecimens for the measurement of genetic and protein expression, and the linkage of that data with clinical findings (Lopez et al., 2011). Since cancer diagnosis and treatment usually begin with diagnostic biopsies followed by surgical resection of the tumor, there are many opportunities to collect valuable biospecimens that are useful in research (Ransohoff and Gourlay, 2010). Also, the use of less invasive approaches is increasing by collecting sera or other body fluids to use with more recent measurement technologies such as GC/LC-MS (Baker et al., 2012). In all cases above, one important key to get precise and reproducible results is performing sample collection, preservation, and preparation consistently for all biological replicates; otherwise, the introduced bias in or across experiments leads to unreal or meaningless results. In addition, by including quality control, samples are useful to monitor the analytical and technical variability in experiments (Boja and Rodriguez, 2012). For example, in GC/LC-MS studies, replicates of a pooled mixture of samples along with spiked in standard compounds with controlled concentrations are used to investigate the reproducibility of the measurements.

**Reagents:** There is a growing need in the field of proteomics for high-quality, well-characterized, and standard reagents that can improve the specificity and reproducibility of proteomic technologies (Paul et al., 2013). One widely used reagent in proteomic research is

**Table 2. Some of Cancer Biomarkers Discovered by Proteomics**

Cancer type	Biomarkers
Breast cancer (Jacquemier et al., 2005; Castronovo et al., 2007; Gonçalves et al., 2008; Montazery-Kordy et al., 2008; Fan et al., 2010; Hooshmand et al., 2013)	Fibrinogen A Fragment; S100A9; 21- protein signature; GCDFP-15 AAG; PARK7; S10A7; GDIR; DDAH1; DDAH2; Versican core protein precursor; AGR2; Ubiquitin; Ferritin light chain; CD13, OSF-2; RS/DJ-1 autoantibody
Esophageal cancer (Fujita et al., 2006; Hatakeyama et al., 2006; Jazii, Najafi et al., 2006; Uemura et al., 2009; Moghanibashi, Jazii et al. 2012; Moghanibashi et al., 2013)	Peroxiredoxin VI autoantibody; Alpha -actinin 4; 67 ku laminin receptor; Rho GDP dissociation inhibitor 2; alpha-enolase; Lamin A/C; nucleodisephosphate kinase A
Gastric cancer (Bai et al., 2011; Kočevár et al., 2012; Sousa et al., 2012; Karimi et al., 2014)	$\alpha$ 1- antitrypsin precursor; Pepsinogen C; Cathepsin B; MAWBP; Vimentin; galectin 1; DEAD-box protein 48 autoantibody; hnRNP A2/B1
Lung cancer (Yanagisawa et al., 2007; Yang et al., 2007; Rahman et al., 2011; Yousefi et al., 2012)	TEF1 $\alpha$ ; A 25-signal Proteomic Signature; Autoantibodies against triosephosphate isomerase and superoxide dismutase (MsSOD); HSP27; Aminopeptidase-P; eIF-5A; 15 distinct MS peaks; PGP 9.5 autoantibody
Liver cancer (Orvisky et al., 2006; Sun et al., 2007; Gray et al., 2009; Ressom et al., 2012; Xiao et al., 2012)	HOP, hnRNP C1/C2; eIF1A; Multiplex serum markers; Ferritin-light-unit; Adenylate kinase-3a-like1; biliverdin reductase B; Tissue ferritin light chain; V10 fragment of vitronectin; Brain-derived neurotrophic factor
Colorectal cancer (Pei et al., 2007; Wu et al., 2008; Wang et al., 2012; Coghlin and Murray, 2013)	CCSA-2, CCSA-3, CCSA-4; SELENBP1; HSP-27; GST; Annexin II; L-FABP

an antibody, which are useful as the capture and detection reagents in proteomics (Ransohoff and Gourlay, 2010). As an alternative, affinity reagents, e.g. aptamers, have recently shown great promise as an adjunct to antibodies (Thiviyanathan and Gorenstein, 2012). These possess protein-binding specificity, similar to antibodies, make them useful as protein capture and detection reagents (Gold et al., 2010).

## Achievements of Proteomics in Cancer Research

Over the past few years, a large number of cancer biomarkers have been discovered by cancer proteomic studies (Tan et al., 2012). Table 1 summarizes some of cancer biomarkers discovered by proteomics.

## Challenges and Future Directions

Proteomics has already delivered significant achievements to understand the cancer, and to identify proteins of potential interest for diagnosis and treatment (Srinivas et al., 2002). However, there are many challenges ahead that should not be underestimated. First, the proteome is highly complex, and current equipment and technologies cannot yet provide a definitive solution for its exploration (Wulfkühle et al., 2003). Moreover, cancer is a multifactorial and diverse disease, so, a great deal of time and effort will be necessary to define its associated proteome modifications and to translate these into practical applications for the clinic (Wulfkühle et al., 2003). However, there are some issues that have not been addressed completely. While running few samples is an easy task with many available technologies, it is still not convenient to perform experiments with tens or hundreds of samples to achieve a reliable data set with appropriate sample size from a statistical analysis point of view. The problem rises as preparing many samples at the same time for a long experiment may not lead to consistent results. Also, preparing samples batch-wise can introduce analytical variability to the experiment. This means that there is tradeoff between sample size and reproducibility of the measurements. One of the main challenges is verification and quantitation of proteins found by discovery step as potential biomarkers. Similarly, identification is still a challenging task for proteomic studies. Even for known compounds, many data base search approaches are not mature enough to come up with confident matches (Karimi et al., 2013). In addition, identification of unknown compounds, i.e. the biomolecules with no good match in the database, still remains as a rigorous procedure, especially when conducting untargeted experiments with lots of possible candidates. On the other hand, using isotope-labeled standards with known compound in targeted studies is not easy in practice. As mentioned before, one way of inferring biological functions is to take advantage of biomolecule interactions by building, developing, and searching biological interaction networks. However, to reveal true underlying interactions, it is required to remove partial

correlations between pairs of biomolecules connected through different pathways. Moreover, there are always some missing or hidden intermediate data, which makes the inference more complicated and less accurate. Finally, if even all these issues are addressed for protein-protein interactions, there is still a more difficult and yet less explored challenge: how to integrate data from different types of omics studies (Ressom et al., 2012).

As a conclusion, proteomics remains a maturing field, but there are substantial reasons to be optimistic about its ability to deliver significant values to cancer research in the near future (Hanash et al., 2008). The fast rate of developments in proteomic technologies and their role in cancer research is increasing steadily (Ferrari, 2005).

## References

- Ardekani AM, Akhondi MM, Sadeghi MR (2008). Application of genomic and proteomic technologies to early detection of cancer. *Arch Iran Med*, **11**, 427-34.
- Bai Z, Ye Y, Liang B, et al (2011). Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer. *Int J Oncol*, **38**: 375-83.
- Baker ES, Liu T, Petyuk VA, et al (2012). Mass spectrometry for translational proteomics: progress and clinical implications. *Genome Med*, **4**, 1-11.
- Bhati A, Garg H, Gupta A, et al (2012). Omics of cancer. *Asian Pac J Cancer Prev*, **13**, 4229-33.
- Boja ES, Rodriguez H (2012). Mass spectrometry based targeted quantitative proteomics: Achieving sensitive and reproducible detection of proteins. *Proteomics*, **12**, 1093-110.
- Brower V (2011). Epigenetics: Unravelling the cancer code. *Nature*, **471**, 12-3.
- Cao Y, DePinho RA, Ernst M, Vousden (2011). Cancer research: past, present and future. *Nat Rev Cancer*, **11**, 749-54.
- Castronovo V, Kischel P, Guillonneau F, et al (2007). Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. *Proteomics*, **7**, 1188-96.
- Chandra H, Reddy PJ, Srivastava S (2011). Protein microarrays and novel detection platforms. *Expert Rev Proteomics*, **8**, 61-79.
- Chang R, Shoemaker R, Wang W (2011). Systematic search for recipes to generate induced pluripotent stem cells. *PLoS Comput Biol*, **7**, 1002300.
- Coghlin C, Murray GI (2013). Progress in the identification of plasma biomarkers of colorectal cancer. *Proteomics*, **13** 2227-8.
- Collins BC, Lau TY, O'Connor DP, Hondermarck H (2009). Cancer proteomics-an evolving battlefield. Conference on Cancer Proteomics 2009: Mechanistic Insights, Technological Advances & Molecular Medicine. *EMBO reports*, **10**, 1202-5.
- Edwards BK, Ward E, Kohler BA, et al (2010). Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer*, **116**, 544-73.
- Etzioni R, Urban N, Ramsey S, et al (2003). The case for early detection. *Nat Rev Cancer*, **3**, 243-52.
- Fan Y, Wang J, Yang Y, et al (2010). Detection and identification of potential biomarkers of breast cancer. *J Cancer Res Clin Oncol*, **136**, 1243-54.

- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*, **127**, 2893-917.
- Ferrari M (2005). Cancer nanotechnology: opportunities and challenges. *Nat Rev Cancer*, **5**, 161-71.
- Fujita Y, Nakanishi T, Hiramatsu M, et al (2006). Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. *Clin Cancer Res*, **12**, 6415-20.
- Ghabaee M, Bayati A, Amir Saroukolaei, et al (2009). Analysis of HLA DR2&DQ6 (DRB1\* 1501, DQA1\* 0102, DQB1\* 0602) haplotypes in Iranian patients with multiple sclerosis. *Cell Mol Neurobiol*, **29**, 109-14.
- Gold L, Ayers D, Bertino J, et al (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One*, **5**, 15004.
- Gonçalves A, Charafe-Jauffret E, Bertucci F, et al (2008). Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. *Mol Cell Proteomics*, **7**, 1420-33.
- Gortzak-Uzan L, Ignatchenko A, Evangelou AI, et al (2007). A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. *J Proteome Res*, **7**, 339-51.
- Gray J, Chattopadhyay D, Beale GS, et al (2009). A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. *BMC Cancer*, **9**, 271.
- Gstaiger M, Aebersold R (2009). Applying mass spectrometry-based proteomics to genetics, genomics and network biology. *Nat Rev Genet*, **10**, 617-27.
- Hainaut P, Plymoth A (2011). Biomarkers in cancer research and treatment: promises and challenges. *Curr Opin Oncol*, **23**, 61.
- Hanash SM, Baik CS, Kallioniemi O (2011). Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. *Nat Rev Clin Oncol*, **8**, 142-50.
- Hanash SM, Pitteri SJ, Faca VM (2008). Mining the plasma proteome for cancer biomarkers. *Nature*, **452**, 571-9.
- Hatakeyama H, Kondo T, et al (2006). Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. *Proteomics*, **6**, 6300-16.
- Hooshmand S, Ghaderi A, Yusoff K, et al (2013). Downregulation of RhoGDI $\alpha$  increased migration and invasion of ER+MCF7 and ER- MDA-MB-231 breast cancer cells. *Cell Adh Migr*, **7**, 297-303.
- International Cancer Genome Consortium, Hudson TJ, Anderson W, et al (2010). International network of cancer genome projects. *Nature*, **464**, 993-8.
- IBM Corp. Released 2011. IBM SPSS Statistics for Windows, V. A., NY: IBM Corp.
- Jacquemier J, Ginestier C, Rougemont J, et al (2005). Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. *Cancer Res*, **65**, 767-79.
- Jazii FR, Najafi Z, Malekzadeh R, et al (2006). Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. *World J Gastroenterol*, **12**, 7104-12.
- Kamangar F, Karimi P (2013). The state of nutritional epidemiology: why we are still unsure of what we should eat?. *Arch Iran Med*, **16**, 483-6.
- Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F (2014). Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev*, In Press.
- Karimi P, Modarresi SZ, Sahraian MA, et al (2013). The relation of multiple sclerosis with allergy and atopy: a case control study. *Iran J Allergy Asthma Immunol*, **12**, 182-9.
- Karimi P, Shahrokni A, Moradi S (2013). Evidence for U.S. Preventive Services Task Force (USPSTF) Recommendations against routine mammography for females between 40-49 years of age. *Asian Pac J Cancer Prev*, **14**, 2137-9.
- Kent W J, Sugnet CW, Furey TS, et al (2002). The human genome browser at UCSC. *Genome Res*, **12**, 996-1006.
- Kocevar N, Odreman F, Vindigni A, Grazio SF, Komel R (2012). Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers. *World J Gastroenterol*, **18**, 1216-28.
- Li G, Xiao Z, Liu J, et al (2011). Cancer: a proteomic disease. *Sci China Life Sci*, **54**, 403-8.
- Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. *Clin Chem*, **48**, 1296-304.
- Lopez E, Wesselink JJ, Lopez I, et al (2011). Technical phosphoproteomic and bioinformatic tools useful in cancer research. *J Clin Bioinforma*, **1**, 26.
- Martin KJ, Fournier MV, Reddy GP, Pardee AB (2010). A need for basic research on fluid-based early detection biomarkers. *Cancer Res*, **70**, 5203-6.
- Maurer HH (2010). Perspectives of liquid chromatography coupled to low-and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology. *Ther Drug Monit*, **32**, 324-7.
- Mishra A, Verma M (2010). Cancer biomarkers: are we ready for the prime time? *Cancers*, **2**, 190-208.
- Moghanibashi M, Jazii FR, Soheili ZS, et al (2012). Proteomics of a new esophageal cancer cell line established from Persian patient. *Gene*, **500**, 124-33.
- Moghanibashi M, Rastgar Jazii F, Soheili ZS, et al (2013). Esophageal cancer alters the expression of nuclear pore complex binding protein Hsc70 and eIF5A-1. *Funct Integr Genomics*, **13**, 253-60.
- Montazery-Kordy H, Miran-Baygi MH, Moradi MH (2008). A data-mining approach to biomarker identification from protein profiles using discrete stationary wavelet transform. *J Zhejiang Univ Sci B*, **9**, 863-70.
- Nezami Ranjbar MR, Zhao Y, Tadesse MG, Wang Y, Ransom HW (2013). Gaussian process regression model for normalization of LC-MS data using scan-level information. *Proteome Sci*, **11**, 13.
- Nicolini C, Pechkova E (2010). An overview of nanotechnology-based functional proteomics for cancer and cell cycle progression. *Anticancer Res*, **30**, 2073-80.
- Orvisky ES, Drake K, Martin BM, et al (2006). Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. *Proteomics*, **6**, 2895-902.
- Pei H, Zhu H, Zeng S, et al (2007). Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. *J Proteome Res*, **6**, 2495-501.
- Pepe MS, Etzioni R, Feng Z, et al (2001). Phases of biomarker development for early detection of cancer. *J Natl Cancer Inst*, **93**, 1054-61.
- Poste G (2012). Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. *Trends Mol Med*, **18**, 717-22.
- Rahman SM, Gonzalez AL Li M, et al (2011). Lung cancer diagnosis from proteomic analysis of preinvasive lesions. *Cancer Res*, **71**, 3009-17.
- Ransohoff DF, Gourlay ML (2010). Sources of bias in specimens for research about molecular markers for cancer. *J Clin Oncol*, **28**, 698-704.

- Ray S, Reddy PJ, Jain R, et al (2011). Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. *Proteomics*, **11**, 2139-61.
- Ressom HW, Xiao JF, Tuli L, et al (2012). Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. *Anal Chim Acta*, **19**, 90-100.
- Rezaee AR, Azadi A, Houshmand M, et al (2013). Mitochondrial and nuclear genes as the cause of complex I deficiency. *Genet Mol Res*, **12**, 3551-4.
- Rual JF, Venkatesan K, Hao T, et al (2005). Towards a proteome-scale map of the human protein-protein interaction network. *Nature*, **437**, 1173-8.
- Rusling JF, Kumar CV, Gutkind JS, et al (2010). Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. *Analyst*, **135**, 2496-511.
- Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, et al (2014) PLGA-Based nanoparticles as cancer drug delivery systems. *Asian Pac J Cancer Prev*, **15**, 517-35.
- Shahrokni A, Karimi P (2012). Geriatric assessment in geriatric oncology; the evolution of authors' network from 2000 to 2012. *J Geriatr Oncol*, **3**, 78-9.
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. *CA Cancer J Clin*, **63**, 11-30.
- Smith RA, Cokkinides V, von Wschenbach AC, et al (2002). American Cancer Society guidelines for the early detection of cancer. *CA Cancer J Clin*, **52**, 8-22.
- Sousa JF, Ham AJ, Whitwell C, et al (2012). Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. *Am J Pathol*, **181**, 1560-72.
- Paul D, Kumar A, Gajbhiye A, Santra MK, Srikanth R (2013). Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. *Biomed Res Int*, **2013**, 783131.
- Srinivas PR, Verma M, Zhao Y, Srivastava S (2002). Proteomics for cancer biomarker discovery. *Clin Chem*, **48**, 1160-9.
- Stoevesandt O, Taussig MJ, He M (2009). Protein microarrays: high-throughput tools for proteomics. *Expert Rev Proteomics*, **6**, 145-57.
- Strassberger V, Fugmann T, Neri D, Roesli C (2010). Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer. *J Proteomics*, **73**, 1954-73.
- Sun W, Xing B, Sun Y, et al (2007). Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis novel protein markers in hepatocellular carcinoma tissues. *Mol Cell Proteomics*, **6**, 1798-808.
- Tan HT, Lee YH, Chung MC (2012). Cancer proteomics. *Mass Spectrom Rev*, **31**, 583-605.
- Thiviyanathan V, Gorenstein DG (2012). Aptamers and the next generation of diagnostic reagents. *Proteomics Clin Appl*, **6**, 563-73.
- Uemura N, Nakanishi Y, Kato H, et al (2009). Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. *Int J Cancer*, **124**, 2106-15.
- Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Resson HW (2012). Ion annotation-assisted analysis of LC-MS based metabolomic experiment. *Proteome Sci*, **21**, 1477-5956.
- Walther TC, Mann M (2010). Mass spectrometry-based proteomics in cell biology. *J Cell Biol*, **190**, 491-500.
- Wang J-J, Liu Y, Zheng Y (2012). Comparative proteomics analysis of colorectal cancer. *Asian Pac J Cancer Prev*, **13**, 1663-6.
- Wang P, Whiteaker JR, Paulovich AG (2009). The evolving role of mass spectrometry in cancer biomarker discovery. *Cancer Biol Ther*, **8**, 1083-94.
- Wu CC, Chen HC, Chen SJ, et al (2008). Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. *Proteomics*, **8**, 316-32.
- Wulfkuehle JD, Liotta LA, Petricoin EF (2003). Proteomic applications for the early detection of cancer. *Nat Rev Cancer*, **3**, 267-75.
- Wulfkuehle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L (2003). Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. *Adv Exp Med Biol*, **532**, 59-68.
- Xiao JF, Varghese RS, Zhou B, et al (2012). LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian Cohort. *J Proteome Res*, **11**, 5914-23.
- Yanagisawa K, Tomida S, Shimada Y, et al (2007). A 25-Signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. *J Natl Cancer Inst*, **99**, 858-67.
- Yang F, Xiao ZQ, Zhang XZ, et al (2007). Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. *J Proteome Res*, **6**, 751-8.
- Yousefi Z, Sarvari J, Nakamura K, et al (2012). Secretomic analysis of large cell lung cancer cell lines using two-dimensional gel electrophoresis coupled to mass spectrometry. *Folia Histochem Cytobiol*, **50**, 368-74.